The pharmacokinetics of a new inotropic catecholamine, N-[2-(3,4-dihydroxyphenyl)-ethyl]-1-methyl-3-(3 carbomylphenyl)-propylamine HCl (KM-13), was studied following i.v. injection of 50 and 100 μg/kg doses to dogs. KM-13 was extracted from plasma using Bond-Elut CN columns and quantified by HPLC with electro-chemical detection. The plasma concentration - time profile of KM-13 following an i.v. bolus was best fitted with a bi-exponential equation and the terminal elimination phase had a half life of about 20 min. The analytical method, with a limit of sensitivity of 2 ng/ml, would appear to have general applicability in studying the pharmacokinetics of synthetic catecholamines.
|Original language||English (US)|
|Number of pages||4|
|Journal||Research Communications in Chemical Pathology and Pharmacology|
|State||Published - Jan 1 1988|
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Pharmacology, Toxicology and Pharmaceutics(all)